P Poignard

Summary

Affiliation: The Scripps Research Institute
Country: USA

Publications

  1. ncbi request reprint gp120: Biologic aspects of structural features
    P Poignard
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Annu Rev Immunol 19:253-74. 2001
  2. doi request reprint Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection
    Laura Adalid-Peralta
    INSERM U764, Clamart, France
    J Leukoc Biol 83:1060-7. 2008
  3. pmc Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2
    Pascal Poignard
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS ONE 7:e42209. 2012
  4. pmc Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies
    Pascal Poignard
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:353-65. 2003
  5. ncbi request reprint Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design
    P W Parren
    Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA
    Immunol Lett 57:105-12. 1997
  6. ncbi request reprint Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design"
    P W Parren
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Immunol Lett 58:125-32. 1997
  7. pmc Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity
    B K Chakrabarti
    IAVI Neutralizing Antibody Center at TSRI, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 85:8217-26. 2011
  8. pmc Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies
    M B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:12198-208. 2001
  9. pmc Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
    D E Mosier
    Department of Immunology IMM7, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:3544-50. 1999
  10. pmc Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
    Aran F Labrijn
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:10557-65. 2003

Research Grants

  1. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Pascal Poignard; Fiscal Year: 2003

Collaborators

Detail Information

Publications14

  1. ncbi request reprint gp120: Biologic aspects of structural features
    P Poignard
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Annu Rev Immunol 19:253-74. 2001
    ..Knowledge of gp120 structure and function should assist in the design of new drugs as well as of an effective vaccine. In the latter case, circumventing the low immunogenicity of the HIV-1 envelope spike is a major challenge...
  2. doi request reprint Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection
    Laura Adalid-Peralta
    INSERM U764, Clamart, France
    J Leukoc Biol 83:1060-7. 2008
    ..Type I IFNs are thus critical in the development of efficient antiviral immune responses in humans, including the production of antiviral antibodies...
  3. pmc Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2
    Pascal Poignard
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS ONE 7:e42209. 2012
    ....
  4. pmc Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies
    Pascal Poignard
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:353-65. 2003
    ....
  5. ncbi request reprint Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design
    P W Parren
    Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA
    Immunol Lett 57:105-12. 1997
    ..Potential vaccines should be designed to elicit responses against native envelope...
  6. ncbi request reprint Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design"
    P W Parren
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Immunol Lett 58:125-32. 1997
    ..Potential vaccines should be designed to elicit responses against native envelope...
  7. pmc Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity
    B K Chakrabarti
    IAVI Neutralizing Antibody Center at TSRI, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 85:8217-26. 2011
    ....
  8. pmc Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies
    M B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:12198-208. 2001
    ....
  9. pmc Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
    D E Mosier
    Department of Immunology IMM7, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:3544-50. 1999
    ..These results reinforce the case for using agents that block all significant HIV-1 coreceptors for effective therapy...
  10. pmc Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
    Aran F Labrijn
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:10557-65. 2003
    ..The results identify hurdles in using CD4i epitopes as targets for antibody-mediated neutralization in vaccine design but also indicate that the CD4i regions could be efficiently targeted by small molecule entry inhibitors...
  11. pmc Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:642-58. 2003
    ..These reengineered gp120s are prospective immunogens that may prove capable of eliciting broadly neutralizing antibodies...
  12. pmc Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  13. ncbi request reprint Identification of peptides from human pathogens able to cross-activate an HIV-1-gag-specific CD4+ T cell clone
    Sara Venturini
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Eur J Immunol 36:27-36. 2006
    ....
  14. pmc Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization
    Sara Venturini
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 76:6987-99. 2002
    ....

Research Grants4

  1. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Pascal Poignard; Fiscal Year: 2003
    ..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..